Roth/MKM Assumes Journey Medical Corp. (DERM) at Buy

Roth/MKM analyst Jason Wittes assumes coverage on Journey Medical Corp. (NASDAQ: DERM) with a Buy rating and a price target of $11.00.

The analyst comments "We are resuming coverage of DERM with a Buy and $11 PT. DFD-29, in our opinion, is positioned to be a best-in-class oral treatment for rosacea, with clinical superiority and an expected expanded label over current market leader Oracea. We estimate DFD-29 will generate at least $200M annually by 2028. DFD-29 has a November 4th Prescription Drug User Fee Act (PDUFA) date. By leveraging DERM’s established dermatology franchise, DFD-29 should push the company to profitability in 2025."

For an analyst ratings summary and ratings history on Journey Medical Corp. click here. For more ratings news on Journey Medical Corp. click here.

Shares of Journey Medical Corp. closed at $5.14 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• Kotak Upgrades Max Financial Services (MAXF:IN) to Buy (1)